JP2023512450A5 - - Google Patents
Info
- Publication number
- JP2023512450A5 JP2023512450A5 JP2022542652A JP2022542652A JP2023512450A5 JP 2023512450 A5 JP2023512450 A5 JP 2023512450A5 JP 2022542652 A JP2022542652 A JP 2022542652A JP 2022542652 A JP2022542652 A JP 2022542652A JP 2023512450 A5 JP2023512450 A5 JP 2023512450A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- amino acid
- heavy chain
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960663P | 2020-01-13 | 2020-01-13 | |
| US62/960,663 | 2020-01-13 | ||
| US202063070728P | 2020-08-26 | 2020-08-26 | |
| US63/070,728 | 2020-08-26 | ||
| US202063091717P | 2020-10-14 | 2020-10-14 | |
| US63/091,717 | 2020-10-14 | ||
| PCT/US2021/013200 WO2021146256A1 (en) | 2020-01-13 | 2021-01-13 | Anti-trem2 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512450A JP2023512450A (ja) | 2023-03-27 |
| JP2023512450A5 true JP2023512450A5 (https=) | 2024-01-22 |
Family
ID=76760857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542652A Pending JP2023512450A (ja) | 2020-01-13 | 2021-01-13 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11124567B2 (https=) |
| EP (1) | EP4090682A1 (https=) |
| JP (1) | JP2023512450A (https=) |
| KR (1) | KR20220131246A (https=) |
| CN (1) | CN115279790A (https=) |
| AU (1) | AU2021208482B2 (https=) |
| BR (1) | BR112022013756A2 (https=) |
| CA (1) | CA3166385A1 (https=) |
| CO (1) | CO2022009744A2 (https=) |
| IL (1) | IL294655A (https=) |
| MX (1) | MX2022008582A (https=) |
| PE (1) | PE20221465A1 (https=) |
| PH (1) | PH12022551650A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP7745557B2 (ja) * | 2020-02-24 | 2025-09-29 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体の使用方法 |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2023192288A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN117624360A (zh) * | 2022-08-26 | 2024-03-01 | 南京融捷康生物科技有限公司 | 一种抗trem2的单域抗体及其用途 |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| CN116041481B (zh) * | 2022-09-13 | 2024-01-19 | 北京湃德智健科技有限公司 | 一种用于检测trem2自身抗体的抗原多肽及其应用 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2024253424A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도 |
| WO2024253420A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026062585A1 (en) * | 2024-09-20 | 2026-03-26 | Novartis Ag | Methods of treatment using anti-trem2 antibodies |
| WO2026062582A1 (en) * | 2024-09-20 | 2026-03-26 | Novartis Ag | Methods of treatment using anti-trem2 antibodies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| TWI541021B (zh) | 2009-03-05 | 2016-07-11 | 艾伯維有限公司 | Ｉｌ－１７結合蛋白 |
| BR112015027313A2 (pt) | 2013-04-29 | 2017-09-26 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado |
| WO2015033223A2 (en) | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2017147509A1 (en) | 2016-02-25 | 2017-08-31 | Marco Colonna | Compositions comprising trem2 and methods of use thereof |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CN109641961A (zh) | 2016-07-22 | 2019-04-16 | 德国神经退行性疾病研究中心 | Trem2切割调节剂及其用途 |
| CA3048224A1 (en) | 2016-12-23 | 2018-06-28 | Bluefin Biomedicine, Inc. | Anti-sez6l2 antibodies and antibody drug conjugates |
| EP3570883A2 (en) | 2017-01-17 | 2019-11-27 | Yeda Research and Development Co. Ltd | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| SG11201907422RA (en) * | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| CN110506055A (zh) * | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| BR112020001060A2 (pt) | 2017-07-27 | 2020-07-14 | Novartis Ag | variantes de trem2 resistentes a shedase |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| EP3665194A4 (en) * | 2017-08-10 | 2021-07-07 | Denali Therapeutics Inc. | AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| US20210186917A1 (en) | 2017-10-17 | 2021-06-24 | The Translational Genomics Research Institute | Trem2 agonists for the stimulation of microglia and methods of identification |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| AU2018383709B2 (en) | 2017-12-12 | 2025-09-11 | Pionyr Immunotherapeutics, Inc. | Anti-TREM2 antibodies and related methods |
| TW201934573A (zh) | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
| WO2019246071A1 (en) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| WO2020037150A2 (en) | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| JP2021534220A (ja) | 2018-08-22 | 2021-12-09 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| CA3120970A1 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| US12351629B2 (en) | 2018-12-10 | 2025-07-08 | Mor Research Applications Ltd. | TREM2 antibodies and uses thereof |
| US20220025065A1 (en) | 2018-12-10 | 2022-01-27 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
| KR20210104079A (ko) | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
| BR112021015656A2 (pt) * | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| CA3134538A1 (en) | 2019-04-03 | 2020-10-08 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
-
2021
- 2021-01-13 JP JP2022542652A patent/JP2023512450A/ja active Pending
- 2021-01-13 MX MX2022008582A patent/MX2022008582A/es unknown
- 2021-01-13 PE PE2022001437A patent/PE20221465A1/es unknown
- 2021-01-13 AU AU2021208482A patent/AU2021208482B2/en active Active
- 2021-01-13 CN CN202180008986.5A patent/CN115279790A/zh active Pending
- 2021-01-13 CA CA3166385A patent/CA3166385A1/en active Pending
- 2021-01-13 KR KR1020227025637A patent/KR20220131246A/ko active Pending
- 2021-01-13 BR BR112022013756A patent/BR112022013756A2/pt unknown
- 2021-01-13 IL IL294655A patent/IL294655A/en unknown
- 2021-01-13 PH PH1/2022/551650A patent/PH12022551650A1/en unknown
- 2021-01-13 EP EP21704639.0A patent/EP4090682A1/en active Pending
- 2021-01-15 US US17/151,006 patent/US11124567B2/en active Active
- 2021-09-17 US US17/478,587 patent/US20220177576A1/en not_active Abandoned
-
2022
- 2022-07-12 CO CONC2022/0009744A patent/CO2022009744A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512450A5 (https=) | ||
| JP2022520868A5 (https=) | ||
| JP2021527656A5 (https=) | ||
| JP7046804B2 (ja) | 改良された血清アルブミン結合剤 | |
| US20200216522A1 (en) | Anti-tau antibodies and methods of use thereof | |
| JP2016147902A5 (https=) | ||
| JP2021533779A5 (https=) | ||
| RU2008129787A (ru) | Фармацевтические композиции с устойчивостью к растворимому сеа | |
| HUE025684T2 (en) | Immunotherapy regimen dependent on ApoE status | |
| CN115298214A (zh) | 用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白 | |
| JP2021534220A5 (https=) | ||
| HRP20192267T1 (hr) | Terapeutski agens ili profilaktički agens za demenciju | |
| JP2022529344A (ja) | 治療及び診断のための新規分子 | |
| JP7772715B2 (ja) | 治療用ｍｕｓｋ抗体 | |
| US20230074436A1 (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| TW202219068A (zh) | 包含ｉｌ—１２及抗ｆａｐ抗體的融合蛋白及其用途 | |
| JP7797203B2 (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| JP2023544545A (ja) | Ｚｉｐ１２抗体 | |
| KR102862890B1 (ko) | Aimp2 및/또는 aimp2 응집체에 특이적으로 결합하는 항체 | |
| US12448441B2 (en) | ZIP12 antibody | |
| WO2025241702A1 (zh) | 靶向hla-g的抗体或其抗原结合片段及其应用 | |
| WO2022103660A1 (en) | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof | |
| JP2024543942A5 (https=) |